Marvel To Move Forward Into Phase I Trial For MB-204 In Partnership With Novatech
(RTTNews) - Marvel Biosciences (MRVL.V) and its subsidiary, Marvel Biotechnology, has signed a letter of intent with Novatech. The signing of the LOI marks an important development milestone for Marvel as MB-204 advances from preclinical development toward first-in-human clinical
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
